Search Results

Adimab, LLC today announced that 12 new partner programs entered clinical development in 2023.

Adimab, LLC announced today that Adimab and LinkedUp Bioscience, Inc. (and related parties) have agreed to resolve litigation.

LinkedUp Bioscience and TianTi Biotherapeutics are pleased to announce the resolution of the lawsuit brought by Adimab, LLC, and related parties.

Adimab, LLC, the global leader in the discovery and engineering of fully human monoclonal and multispecific antibodies, today announced that it entered into partnership agreements with 10 new companies in 2023.

Ablexis, LLC today announced a license agreement with Adimab, LLC (“Adimab”).

Ono Pharmaceutical Co., Ltd. announced that it has entered into a drug discovery collaboration agreement with Adimab, LLC, the global leader in the discovery and optimization of fully human monoclonal and bispecific antibodies, to discover and develop innovative antibody drugs in the oncology field.

Adimab, LLC, the global leader in the discovery and optimization of fully human monoclonal and bispecific antibodies, today announced that it entered into partnership agreements with 11 new companies in 2022.

Adimab, LLC, the global leader in the discovery and optimization of fully human monoclonal and bispecific antibodies, today announced that seven new partner programs entered clinical development in 2022, including programs by Biotheus, Dragonfly, Innovent, Surface Oncology, and a program with financial support from the Gates Foundation.